 By David Bautz, PhD NASDAQ:BVXV READ THE FULL BVXV RESEARCH REPORT Business Update Second Cohort of Phase 3 Trial Fully Enrolled On November 18, 2019, BiondVax Pharmaceuticals, Ltd. NASDAQ:BVXV announced that the second cohort of the Phase 3 trial of the companys universal influenza vaccine candidate, M-001, was fully enrolled. A total of 12,463 adults aged 50 years and older have been 